1. Home
  2. CLSD vs HNNA Comparison

CLSD vs HNNA Comparison

Compare CLSD & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLSD
  • HNNA
  • Stock Information
  • Founded
  • CLSD 2011
  • HNNA 1989
  • Country
  • CLSD United States
  • HNNA United States
  • Employees
  • CLSD N/A
  • HNNA N/A
  • Industry
  • CLSD Biotechnology: Pharmaceutical Preparations
  • HNNA Investment Managers
  • Sector
  • CLSD Health Care
  • HNNA Finance
  • Exchange
  • CLSD Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • CLSD 81.2M
  • HNNA 94.7M
  • IPO Year
  • CLSD 2016
  • HNNA N/A
  • Fundamental
  • Price
  • CLSD $0.95
  • HNNA $12.10
  • Analyst Decision
  • CLSD Strong Buy
  • HNNA
  • Analyst Count
  • CLSD 6
  • HNNA 0
  • Target Price
  • CLSD $5.33
  • HNNA N/A
  • AVG Volume (30 Days)
  • CLSD 214.9K
  • HNNA 6.6K
  • Earning Date
  • CLSD 03-11-2025
  • HNNA 02-13-2025
  • Dividend Yield
  • CLSD N/A
  • HNNA 4.54%
  • EPS Growth
  • CLSD N/A
  • HNNA 75.66
  • EPS
  • CLSD N/A
  • HNNA 1.12
  • Revenue
  • CLSD $7,703,000.00
  • HNNA $33,210,000.00
  • Revenue This Year
  • CLSD N/A
  • HNNA N/A
  • Revenue Next Year
  • CLSD $91.87
  • HNNA N/A
  • P/E Ratio
  • CLSD N/A
  • HNNA $10.80
  • Revenue Growth
  • CLSD 248.39
  • HNNA 38.27
  • 52 Week Low
  • CLSD $0.80
  • HNNA $6.60
  • 52 Week High
  • CLSD $2.12
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • CLSD 43.06
  • HNNA 47.38
  • Support Level
  • CLSD $1.00
  • HNNA $11.97
  • Resistance Level
  • CLSD $1.09
  • HNNA $13.12
  • Average True Range (ATR)
  • CLSD 0.07
  • HNNA 0.45
  • MACD
  • CLSD -0.01
  • HNNA -0.03
  • Stochastic Oscillator
  • CLSD 16.30
  • HNNA 26.62

About CLSD Clearside Biomedical Inc.

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: